In this January issue, we wish to share with you our achievements during 2019. We will also provide you with the current approach by EU and UK authorities regarding CBD products on the market, and we will discuss innovation and infant nutrition clinical research. Also, meet us next month at [...]
No doubt that breastmilk is the best nutrition for infants. Therefore, health authorities worldwide recommend exclusive breastfeeding for 4-6 months. But especially in industrialised countries, only 25 % of infants are exclusively breastfed at the age of 6 months. Manufacturers of infant nutrition are committed to improving their formulas and to mimic the composition [...]
In the last years, numerous CBD containing food products appeared on the European market. In contrast to tetrahydrocannabinol (THC), CBD is not classified as a narcotic, and its possession and consumption for consumers is in principle legal. This does not automatically mean that CBD can be legally sold as a food ingredient, however. So, [...]
Another year has gone by and, as usual, a&r has been involved in amazing projects. We also had the chance to meet former and new clients; we visited trade shows and attended expert events all around the world. Regulatory services Substance-based medical device In the last one and a half years, [...]
We dedicate this December issue to our overview of ingredients, regulatory highlights of 2019, and recent nutraceutical market information. […]
We are happy to invite you to our next webinar! Substance-based medical devices under MDR – Steps you need to take! by our experts Dr. Marlen Landschreiber and Dr. Solveigh Krusekopf Date: 29th of January 2020 Time: 3:00pm (CET) – 30 min talk and 15 min Q&A Major changes will come to pass under [...]
Cannabidiol (CBD) The market of cannabidiol (CBD)-containing products has been booming in Europe, Canada and the USA while regulations were clearly lagging behind. In January, the European Commission updated the Novel Food Catalogue regarding Cannabis sativa L., Cannabidiol and Cannabinoids. According to the Novel Food Catalogue, more or less all products consisting of [...]
The most prominent ingredient during this year was certainly cannabis/cannabidiol (CBD). The market of CBD-containing products as food/food supplements is thriving, but the classification of CBD products as novel food has serious repercussions for the industry. Plant-based proteins are another hot trend that is here to stay, as part of the so-called plant-based revolution. [...]
Dear Colleagues and Friends, The year is coming to an end and we would like to thank all our customers, business partners, and friends for the great cooperation we have enjoyed with you. We wish you a very successful upcoming business year and look forward to great projects and partnerships with you and your [...]
Consumers’ perception of healthy living is shifting from only addressing physical health to a more holistic approach where exercise, food and mental wellbeing play a key role. According to Euromonitor, 62% of global consumers associate health with mental wellbeing. Euromonitor also reported that one of the five trends impacting consumers’ health and nutrition is [...]
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
MeriCal, a contract manufacturer and packager of high quality probiotics and nutritional supplements, has recently signed a final commercial agreement to acquire Global Health Industries (GHI).
GHI is highly specialized in the manufacturing of probiotics. MeriCal’s acquisition of GHI will increase market competitiveness and will drive international expansion.
It has been reported by Bloomberg that Nestle is currently the top bidder for Merck KGaA’s, offering up to $5 billion. According to the sources, companies previously interested in this business have dropped out of the bidding, including Perrigo and Bain and Cinven, while Reckitt Benckiser and Mylan are still in the running. Nestle, frontrunner at the moment, has been strengthening its health business, and acquired Atrium Innovations for $2.3 billion last month.
Global ingredients company DSM has acquired Biocare Copenhagen, expanding their gut health portfolio for an undisclosed price. With this acquisition, DSM will increase its gut health portfolio with probiotics. The company has showed interest in gut health ingredients beyond the well-known indications for digestive and immune health.
Earlier this month, Nestlé announced that it agreed to acquire Atrium Innovations (transaction to be completed Q1 2018). Atrium is globally recognized for the development, production, and commercialization of innovative and scientifically-proven natural health products. Its strategy is complementary with Nestlé science-based natural solutions for consumers and health care professionals. With this acquisition, Nestlé will extend its consumer healthcare nutrition portfolio, and Atrium will compete more effectively in the global market place.
A clear evidence that silos between industries will be breaking down in the future.
Walgreens has announced that it will invest $416 million to acquire 40% stake in Sinopharm Holding GuoDa Drug Store Co., Ltd (GuoDa). Walgreens is the second-largest pharmacy store chain in the US behind CVS Health. GuoDa retails pharmaceutical and healthcare products across China.
Walgreens was already present in China through Alliance Boots. This new investment highlights the interest of Walgreens in the Chinese fast-paced retail pharmacy business.
Walgreens investment took place in the same week that CVS announced to spend $69 billion to buy Aetna, the third largest health insurer in the U.S. CVS also has international operations but has not revealed interest in China yet.
Frutarom licensed AB-FORTIS in 2012 and now is buying the patent. AB-Fortis is a micro-encapsulation system that allows delivering 100% of the recommended daily amount of iron in a single dose, with high bioavailability and no adverse effects in taste or during digestion. “AB-Fortis expands Frutarom’s diverse product portfolio in the growing field of specialty healthy ingredients,” says Dr Raimund C. Hoenes, General Manager of Frutarom Health. With this transaction, AB-BIOTICS will focus on its probiotics business, which represents 87% of its total sale. In addition, the sales of AB-FORTIS will support the great R&D investment that AB-BIOTICS has done to reinforce their current probiotics concepts.
Relevium has signed a non-binding agreement to acquire an American nutraceutical e-brand that sell their products mainly through Amazon.
Relevium is a publicly traded company focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness market. The value of this transaction is currently estimated at 1,15 mill EUR and it is foreseen to be closed on the 30th of November this year.
Last summer, Relevium completed the acquisition of BioGanix, another e-commerce brand and they have plans to conclude more transactions with e-retail brands in the future.
In September, color-ingredients manufacturer Roha (India) completed the acquisition of New Foods Industry S.p.A., an Italian company.
Roha is a leader in the color-ingredients market worldwide, and New Foods Industry is specialized in dry ingredients for the food and beverage industries.
This is the third acquisition for Roha during this year, enabling its further consolidation in the color business.